Zobrazeno 1 - 10
of 470
pro vyhledávání: '"Invited Speaker Presentation"'
Publikováno v:
The Journal of Headache and Pain
Background and state of the art Migraine (M) is the seventh leading cause of years of life lost to disability (YLDs) worldwide, responsible for 2.9% of all YLDs, more than half of all YLDs attributable to neurological disorders [1]. Its negative effe
Autor:
Gianluca Coppola
Publikováno v:
The Journal of Headache and Pain
Background During recent years, various experimental data suggested that the functional state of the migraineur’s brain fluctuates in relation with the cyclical recurrence of the migraine attack. This was historically observed with the methods of c
Publikováno v:
The Journal of Headache and Pain
Sjaastad & Spierings described “Hemicrania continua” (HC) in 1984[1]. In 2001, succinct criteria were presented[2]: permanent hemicrania, pain intensity: mild-moderate, (but occasionally - severe) and indomethacin dosage < 150 mg daily. In additi
Publikováno v:
The Journal of Headache and Pain
System-wide adoption of Personalised Healthcare requires an active and flexible but highly integrated infrastructure, joining many different competences and technologies and allowing continuous upgrading, also through self-learning processes. In this
Autor:
Paola Torelli, Gian Camillo Manzoni
Publikováno v:
The Journal of Headache and Pain
The term “chronic migraine” (CM) was officially introduced in 2004 in the second edition of the International Classification of Headache Disorders (ICHD-2), which included it in the chapter on migraine at the three-digit level (code 1.5.1) among
Autor:
Nicola Vanacore, Sabina Cevoli, Licia Grazzi, Cinzia Aurilia, Gabriella Egeo, Paola Torelli, Gennaro Bussone, Pietro Cortelli, Luisa Fofi, Gian Camillo Manzoni, Piero Barbanti
Publikováno v:
The Journal of Headache and Pain
According to the existing classification chronic migraine (CM) is a primary headache that occurs on 15 or more days per month for more than 3 months and has the features of migraine on at least 8 days per month. In Europe, CM prevalence ranges from 2
Autor:
Stephen Senn
Publikováno v:
Trials
Randomisation in clinical trials continues to be controversial and to be attacked on ethical, practical and philosophical grounds. Whatever the practical, moral or philosophical limitations of randomisation may be, many of the attacks reveal that the
Autor:
Weimin Liu, Peter D. Walsh, Martine Peeters, Martin N. Muller, Gerald H. Learn, David Morgan, Sabrina Locatelli, Julian C. Rayner, Jean-Bosco N. Ndjango, Eitel Mpoudi-Ngole, Alexander V. Georgiev, Rebecca S. Rudicell, Crickette M. Sanz, Yingying Li, George M. Shaw, Paul M. Sharp, Brandon F. Keele, Beatrice H. Hahn, Joel D. Robertson, Philip J. Kranzusch, Eric Delaporte, Mary Katherine Gonder
Publikováno v:
Malaria Journal, Vol 9, Iss Suppl 2, p I6 (2010)
Europe PubMed Central
Malaria Journal
Europe PubMed Central
Malaria Journal
Plasmodium falciparum is the most prevalent and lethal of the malaria parasites infecting humans, yet the origin and evolutionary history of this important pathogen remain controversial. Here we develop a single-genome amplification strategy to ident
Autor:
Peter Horby
Publikováno v:
Trials
Europe PubMed Central
Europe PubMed Central
In the closing plenary lecture, Prof Peter Horby describes the challenges of conducting clinical trials in emergency settings.